Teva Copaxone price estimated at $7,000-$10,000 per patient per year, company tells Lehman Bros. meeting.
Executive Summary
TEVA COPAXONE PRICE WILL BE $7,000-$10,000 PER YEAR PER PATIENT, the company said as it awaits approval of the multiple sclerosis therapy Copolymer-1. Teva Chief Financial Officer Dan Sueskind disclosed the estimated price range of Copaxone at a Lehman Brothers analysts meeting in London May 8-9.